IL-28A,IL-28B,and IL-29: Promising cytokines with type I interferon-like properties |
| |
| Authors: | Katrin Witte Ellen Witte Robert Sabat Kerstin Wolk |
| |
| Affiliation: | 1. Faculty of Medicine, Department of Medical Genetics, Bulent Ecevit University, Zonguldak, Turkey;2. Faculty of Sciences and Arts, Department of Molecular Biology and Genetics, Bulent Ecevit University, Zonguldak, Turkey;3. Faculty of Medicine, Department of Pediatric Neurology, Harran University, Sanl?urfa, Turkey;4. Faculty of Medicine, Department of Biostatistics, Bulent Ecevit University, Zonguldak, Turkey;5. Faculty of Medicine, Department of Pediatrics, Bulent Ecevit University, Zonguldak, Turkey;1. Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China;2. Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China;3. Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;4. Department of Laboratory Medicine, Guangzhou First People''s Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China |
| |
| Abstract: | IL-28A, IL-28B and IL-29 (also designated type III interferons) constitute a new subfamily within the IL-10–interferon family. They are produced by virtually any nucleated cell type, particularly dendritic cells, following viral infection or activation with bacterial components, and mediate their effects via the IL-28R1/IL-10R2 receptor complex. Although IL-28/IL-29 are closer to the IL-10-related cytokines in terms of gene structure, protein structure, and receptor usage, they display type I interferon-like anti-viral and cytostatic activities. Unlike type I interferons, the target cell populations of IL-28/IL-29 are restricted and mainly include epithelial cells and hepatocytes. These properties suggest that IL-28/IL-29 are potential therapeutic alternatives to type I interferons in terms of viral infections and tumors. This review describes the current knowledge about these cytokines. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
